{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:42:57Z","timestamp":1794026577652,"version":"4.8.0"},"reference-count":17,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinical interpretation of trace results by Xpert MTB\/RIF Ultra assay (Ultra) used as an initial diagnostic test for tuberculosis (TB) may be challenging. The aim of the study was to evaluate the frequency and epidemiology of trace readouts in routine clinical practice in a low TB prevalence setting and to propose guidance on how to manage patients with trace calls considering the data available (clinical, radiological, bacteriological etc.).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A retrospective, observational, monocentric study was conducted at IRCCS Azienda Ospedaliero-Universitaria of Bologna, Italy between November 2017\u2014December 2020. Presumptive TB patients with at least one Ultra trace result during diagnostic workup before treatment were included in the study. Patients with ongoing anti-TB treatment at the time of the trace call result or with no clinical data available were excluded from the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty-nine presumptive TB patients with Ultra trace readouts were included in the study (mean age 37.0 years, 61% males). Four patients had a history of TB in the last 2 years. Twenty-five (42.4%) of the 59 samples with trace results were respiratory material. 57\/59 (96.6%) patients started anti-TB treatment soon after obtaining trace results, based on clinical, radiological or other information available, while for two patients with a recent history of TB the trace result did not lead to anti-TB treatment. Culture was positive for\n                      <jats:italic>M<\/jats:italic>\n                      .\n                      <jats:italic>tuberculosis<\/jats:italic>\n                      for 31\/59 (52.5%) samples with trace calls: 13\/25 (52.0%) were respiratory samples and 18\/33 (54.5%) non-respiratory samples. The clinical and\/or radiological findings of 47\/57 (82.4%) patients given anti-TB therapy improved during treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In low TB incidence settings, Ultra trace calls in presumptive TB patients should be considered as true-positive and treatment should be started promptly, except in cases of recent history of TB, where careful evaluation of other diagnostic criteria is necessary before starting anti-TB treatment. A decisional algorithm for clinical management is proposed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0272997","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T13:45:42Z","timestamp":1660311942000},"page":"e0272997","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Evaluation of trace calls by Xpert MTB\/RIF ultra for clinical management in low TB burden settings"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3787-0846","authenticated-orcid":true,"given":"Alberto","family":"Amedeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Beci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3838-4041","authenticated-orcid":true,"given":"Maddalena","family":"Giglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6423-8358","authenticated-orcid":true,"given":"Giulia","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bisognin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7483-0336","authenticated-orcid":true,"given":"Federico","family":"Chiarucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Dal Monte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Tadolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"pone.0272997.ref001","unstructured":"World Health Organization Global Tuberculosis Report 2021. Geneva: World Health Organization; 2021. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240037021"},{"key":"pone.0272997.ref002","unstructured":"Cepheid. Xpert MTB\/RIF Ultra\u2014Commercial Brochure. 2017. Available from: http:\/\/www.cepheid.com\/administrator\/components\/com_productcatalog\/library-files\/5658293188378fce922d67a8e0ac7017-Xpert-MTBRIF-Ultra-Brochure-Commercial-CEIVD-3098-01.pdf"},{"issue":"2","key":"pone.0272997.ref003","first-page":"e01717","article-title":"Added Value of Xpert MTB\/RIF Ultra for Diagnosis of Pulmonary Tuberculosis in a Low-Prevalence Setting","volume":"57","author":"O Opota","year":"2019","journal-title":"J ClinMicrobiol"},{"key":"pone.0272997.ref004","unstructured":"Foundation for Innovative New Diagnostics. 2017. Report for WHO. A multicentre non-inferiority diagnostic accuracy study of the Ultra assay compared to the Xpert MTB\/RIF assay. Geneva, Switzerland. Available from https:\/\/www.finddx.org\/reports-and-landscapes\/a-multicentre-non-inferiority-diagnostic-accuracy-study-of-the-ultra-assay-compared-to-the-xpert-mtb-rif-assay\/"},{"key":"pone.0272997.ref005","doi-asserted-by":"crossref","first-page":"e00812","DOI":"10.1128\/mBio.00812-17","article-title":"The New Xpert MTB\/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing","volume":"8","author":"S Chakravorty","year":"2017","journal-title":"mBio"},{"key":"pone.0272997.ref006","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1473-3099(17)30691-6","article-title":"Xpert MTB\/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study","volume":"18","author":"SE Dorman","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"pone.0272997.ref007","unstructured":"World Health Organization meeting report for a technical expert consultation: Non-inferiority analysis of Xpert MTB\/RIF Ultra compared to Xpert MTB\/RIF. Geneva: World Health Organization; 2017. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-HTM-TB-2017.04"},{"key":"pone.0272997.ref008","unstructured":"World Health Organization consolidated guidelines on tuberculosis: Module 3: Diagnosis\u2014Rapid diagnostics for tuberculosis detection 2021 update. Geneva: World Health Organization; 2021. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240029415"},{"key":"pone.0272997.ref009","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.cmi.2019.03.021","article-title":"The rapid molecular test Xpert MTB\/RIF ultra: towards improved tuberculosis diagnosis and rifampicin resistance detection","volume":"25","author":"O Opota","year":"2019","journal-title":"ClinMicrobiol Infect"},{"key":"pone.0272997.ref010","doi-asserted-by":"crossref","first-page":"e0201934","DOI":"10.1371\/journal.pone.0201934","article-title":"Improvement of Mycobacterium tuberculosis detection by Xpert MTB\/RIF Ultra: A head-to-head comparison on Xpert-negative samples","volume":"13","author":"F Bisognin","year":"2018","journal-title":"PLoS One"},{"key":"pone.0272997.ref011","doi-asserted-by":"crossref","first-page":"100094","DOI":"10.1016\/j.jctube.2019.100094","article-title":"Comparative evaluation of Xpert MTB\/RIF and the new Xpert MTB\/RIF ultra with respiratory and extra-pulmonary specimens for tuberculosis case detection in a low incidence setting","volume":"15","author":"C Piersimoni","year":"2019","journal-title":"J ClinTuberc Other Mycobact Dis"},{"key":"pone.0272997.ref012","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4103\/ijmy.ijmy_200_20","article-title":"Multicenter evaluation of xpert MTB\/RIF ultra tests reporting detection of \"Trace\" of Mycobacterium tuberculosis DNA","volume":"10","author":"E Mazzola","year":"2021","journal-title":"Int J Mycobacteriol"},{"key":"pone.0272997.ref013","doi-asserted-by":"crossref","first-page":"e0176186","DOI":"10.1371\/journal.pone.0176186","article-title":"Diagnosis of smear-negative tuberculosis is greatly improved by Xpert MTB\/RIF","volume":"12","author":"G Lombardi","year":"2017","journal-title":"PLoS One"},{"key":"pone.0272997.ref014","unstructured":"World Health Organization Myanmar. Fourth National Tuberculosis Prevalence Survey Report (2017\u20132018). Myanmar: World Health Organization, 2020. Available from: https:\/\/www.mohs.gov.mm\/Main\/content\/publication\/tuberculosis-4th-nationwide-tb-prevalence-survey-2017-2018"},{"key":"pone.0272997.ref015","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S2213-2600(19)30370-4","article-title":"Xpert MTB\/RIF Ultra and Xpert MTB\/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study","volume":"8","author":"H Mishra","year":"2020","journal-title":"Lancet Respir Med"},{"key":"pone.0272997.ref016","first-page":"CD009593","article-title":"Xpert Ultra versus Xpert MTB\/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis","volume":"2","author":"JS Zifodya","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0272997.ref017","unstructured":"World Health Organization operational handbook on tuberculosis. Module 3: diagnosis\u2014rapid diagnostics for tuberculosis detection. Geneva: World Health Organization; 2020. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240030589"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0272997","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T12:24:48Z","timestamp":1700915088000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0272997"}},"subtitle":[],"editor":[{"given":"Padmapriya P.","family":"Banada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":17,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0272997","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]}}}